Prostate cancer is the second most common cancer in men, and rates are on the rise. By 2030 there’ll be 1.7 million men living with prostate cancer. It’s already killing hundreds of thousands of men each year, and those who survive face serious side effects.
We can’t afford to let this continue.
So we’re taking action.
We’ve spent years learning how to tackle the toughest cancer challenges in innovative ways. Now it's time to draw a line in the sand.
By 2030 we’ll halve the number of men dying from prostate cancer.
We'll also halve the number of men facing serious ongoing side effects from prostate cancer treatment.
“I'd like to imagine my son growing up in a world where prostate cancer can be cured. In a world where the way Dad freely talked about his health and his regular health checks isn’t unique, but the norm.”
Cancer research and care is full of difficult problems, but we’ve never been afraid of a challenge. We’ve spent years funding the most innovative and forward-thinking projects, getting the best researchers together to tackle the thorniest issues.
We’re focused on what works for men. From early detection through to diagnosis, treatment, and support: we’re not just looking for a cure. We’re looking for quality of life.
The plan of attack
1. Taking action early
Helping men know the signs, symptoms and risk factors for prostate cancer.
2. Bright minds brought together
We’re bringing the best minds from around the world together to collaborate.
3. Tackling biology
Increasing the knowledge of the most lethal prostate cancer tumours, and how to slow or stop its progression.
4. Reducing side effects
No matter where they are in the world, men and their families and carers must have access to services and support.
5. Affordable treatment
We’re influencing governments to provide affordable treatment and to get new treatments into practice faster.
6. Tailored treatments, precision care
Personalised treatment is the new frontier of cancer research. From distinguishing between harmless and lethal cancers, to taking into account genes, lifestyle and environment: it means a better outcome for men.
7. Helping men make tough choices
Men need the right info to understand their diagnosis and make an informed decision when it comes to treatment.
8. Raising the standard
We’re identifying excellence in prostate cancer treatment and care, to reduce the number of men who aren’t getting the best outcome possible.
9. Global initiatives
Our three largest investments in prostate cancer are global programs that will mean better outcomes for men everywhere.
We’ve funded more than 1,200 men’s health projects, in Ireland and around the world. Here’s a snapshot of our work in prostate cancer.
Projects that span the globe
We link up researchers around the world and get results faster by encouraging collaboration. We share our successes and our failures, so the scientific community doesn’t waste time on duplicate research.
Global Action Plan
Our Global Action Plan (GAP) is an international research initiative that brings researchers together to tackle the toughest challenges in prostate and testicular cancer. Since GAP launched in 2011, it has formed 7 large-scale global initiatives supporting 350 researchers from 90 institutions across 21 countries.
TrueNTH is a revolutionary global care program that helps men living with prostate cancer to access care and support that improves quality of life before, during and after treatment. It focuses on empowering men to make informed decisions when it comes to treatment and side effects. TrueNTH operates across 6 countries with a team of more than 80 collaborators.
Our Prostate Cancer Outcomes (PCO) initiatives are transforming prostate cancer healthcare globally by building a better understanding of men’s experiences. By compiling reports from both doctors and patients throughout treatment and comparing this across regions, we’re forming a new benchmark for prostate cancer care. This program is working in 7 countries, with 40 collaborators and researchers.
Prostate cancer research breakthrough
Movember Foundation funded research has discovered that men have a genetic “fingerprint” within their prostate cancer cells which will help build a more tailored treatment plan for men. This will help avoid overtreatment and side effects.
In addition to large-scale efforts that span the globe, we’re also making strides for men in Ireland, in partnership with Irish Cancer Society (ICS).
The CASE initiative is a 2-3 year action research programme funded with €390,000. This will pilot at least two sites where specialist nurses will work with men following prostate cancer treatment. They will work alongside the current delivery of specialist nursing care to men during diagnosis and treatment.
The function of the pilot programme is to enhance current clinical care through the provision of specialist nurse follow-up for side effects, which can cause men distress at various stages following prostate cancer treatment. The goal is to reduce the impact of treatment consequences on the patient in the long term by providing care, advice, support and education to the patient experiencing side effects. The Pilot Project will be based in Galway University Hospital and St. James’s Hospital, Dublin.
€350,000 in funding has been awarded to Molecular Medicine Ireland to establish the first IPCOR in Ireland. This will monitor, benchmark and publicly report annually on outcomes of prostate cancer treatment and care. The project will be led by Consultant Urologist, Dr David Galvin, Chairperson and Clinical Lead, Prostate Cancer Committee, National Cancer Control Programme (NCCP). Funding for a further four years will be made available to bring the total IPCOR fund amount to €1.75million over five years.
This programme is part of TrueNTH Ireland was developed by the Irish Cancer Society with €97,000 of funding from the Movember Foundation. The programme provides support and information to men with prostate cancer in their local cancer support centres.
The six session programme aims to enhance the physical and psychosocial wellbeing and quality of life for prostate cancer survivors by identifying and responding to supportive care needs, developing healthy coping strategies and managing lifestyle changes. The programme is active in 12 cancer support centres right around Ireland and was attended by 200 men who have had a diagnosis of prostate cancer.
Irish Programme for Stratified Prostate Cancer Therapy (iPROSPECT)
The Movember Foundation also awarded the iPROSPECT Programme €745,140 in funds. This programme consists of connected and supported projects integrated to transform the current practice to a more individual and personalized treatment of patients with metastatic prostate cancer in order to improve patient outcomes.
The iPROSPECT programme consists of three connected projects:
The Prostate Cancer – Bone Marrow Mesenchymal Stem Cells Paraendocrine Axis in the metastatic tumour microenvironment: Impact on tumour response to metastatic targeted therapies.
The Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy.
The Evolution of the CRPC Epigenome and its Clinical Application for delivering Precision Medicine.
This research team will deliver a programme of stratified oncology therapy for patients with prostate cancer.
We’re already seeing results, but there’s still work to be done.
We’ve pushed prostate cancer research forward 50 years, but there’s so much yet to be done. Men are still facing life or death questions, invasive treatments, and serious side effects. They’re dying too young.
To get to where we want to be by 2030,
we need your help.